51 related articles for article (PubMed ID: 25811342)
1. High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1-Infected Patients.
Lindahl K; Hörnfeld E; Ståhle L; Carlsson T; Weiland O; Parke Å; Schvarcz R
Ther Drug Monit; 2015 Dec; 37(6):745-50. PubMed ID: 25811342
[TBL] [Abstract][Full Text] [Related]
2. Lower Ribavirin Plasma Concentrations in HCV/HIV-Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar Dosage.
Deenen MJ; de Kanter CT; Dofferhoff AS; Grintjes-Huisman KJ; van der Ven AJ; Fleuren HW; Gisolf EH; Koopmans PP; Drenth JP; Burger DM
Ther Drug Monit; 2015 Dec; 37(6):751-5. PubMed ID: 26102531
[TBL] [Abstract][Full Text] [Related]
3. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.
Lindahl K; Stahle L; Bruchfeld A; Schvarcz R
Hepatology; 2005 Feb; 41(2):275-9. PubMed ID: 15660393
[TBL] [Abstract][Full Text] [Related]
4. New proposal for response-guided peg-interferon-plus-ribavirin combination therapy for chronic hepatitis C virus genotype 2 infection.
Abe H; Aida Y; Ishiguro H; Yoshizawa K; Seki N; Miyazaki T; Itagaki M; Sutoh S; Ika M; Kato K; Shimada N; Tsubota A; Aizawa Y
J Med Virol; 2013 Sep; 85(9):1523-33. PubMed ID: 23775277
[TBL] [Abstract][Full Text] [Related]
5. Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy.
Donnerer J; Grahovac M; Stelzl E; Kessler HH; Bankuti C; Stadlbauer V; Stauber RE
Pharmacology; 2006; 76(3):136-40. PubMed ID: 16410679
[TBL] [Abstract][Full Text] [Related]
6. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1.
Akuta N; Suzuki F; Seko Y; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
J Med Virol; 2012 Jul; 84(7):1097-105. PubMed ID: 22585728
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C.
Hara T; Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Kumada H
J Med Virol; 2013 Oct; 85(10):1746-53. PubMed ID: 23861088
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type.
Fülöp B; Mihm U; Rohde P; Buggisch P; Schlosser B; Biermer M; Brodzinski A; Fischer J; Böhm S; van Bömmel F; Sarrazin C; Berg T
J Viral Hepat; 2016 Nov; 23(11):866-872. PubMed ID: 27346846
[TBL] [Abstract][Full Text] [Related]
11. Improvement of liver histopathology in patients with hepatitis C after interferon and ribavirin combination therapy.
Petrenkiene V; Gudinaviciene I; Jonaitis L; Kupcinskas L
Medicina (Kaunas); 2004; 40(10):962-8. PubMed ID: 15516819
[TBL] [Abstract][Full Text] [Related]
12. Response-guided therapy for hepatitis C genotype 2 and 3 in those with HIV coinfection.
Win LL; James P; Wong DK
Dig Dis Sci; 2014 Aug; 59(8):1946-9. PubMed ID: 24846795
[TBL] [Abstract][Full Text] [Related]
13. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency.
Bruchfeld A; Lindahl K; Ståhle L; Söderberg M; Schvarcz R
Nephrol Dial Transplant; 2003 Aug; 18(8):1573-80. PubMed ID: 12897097
[TBL] [Abstract][Full Text] [Related]
14. Individualization of antiviral treatment regimens for chronic hepatitis C.
Paulon E; Naoumov NV
Eur J Gastroenterol Hepatol; 2006 Apr; 18(4):321-5. PubMed ID: 16538101
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy.
Amanzada A; Goralczyk AD; Reinhardt L; Moriconi F; Cameron S; Mihm S
BMC Infect Dis; 2014 Sep; 14():503. PubMed ID: 25227310
[TBL] [Abstract][Full Text] [Related]
16. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis.
Bruchfeld A; Lindahl K; Schvarcz R; Ståhle L
Ther Drug Monit; 2002 Dec; 24(6):701-8. PubMed ID: 12451285
[TBL] [Abstract][Full Text] [Related]
17. Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C.
Maeda Y; Kiribayashi Y; Moriya T; Maruhashi A; Omoda K; Funakoshi S; Murakami T; Takano M
Ther Drug Monit; 2004 Feb; 26(1):9-15. PubMed ID: 14749543
[TBL] [Abstract][Full Text] [Related]
18. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome.
Muller MP; Dresser L; Raboud J; McGeer A; Rea E; Richardson SE; Mazzulli T; Loeb M; Louie M;
Pharmacotherapy; 2007 Apr; 27(4):494-503. PubMed ID: 17381375
[TBL] [Abstract][Full Text] [Related]
19. Improved HPLC method for the determination of ribavirin concentration in red blood cells and its application in patients with COVID-19.
Liu L; Guo S; Che C; Su Q; Zhu D; Hai X
Biomed Chromatogr; 2022 Jul; 36(7):e5370. PubMed ID: 35297066
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir.
Kirby BJ; Symonds WT; Kearney BP; Mathias AA
Clin Pharmacokinet; 2015 Jul; 54(7):677-90. PubMed ID: 25822283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
